2 weeks Ago By ABMN Staff
StockNews.com cut shares of Medpace ( NASDAQ:MEDP – Free Report ) from a buy rating to a hold rating in a research note released on Friday morning. A number of other research analysts have also recently commented on the stock.
Deutsche Bank Aktiengesellschaft cut their price target on shares of Medpace from $395.00 to $336.00 and set a hold rating for the company in a research note on Wednesday, July 24th.
Guggenheim lowered their price target on Medpace from $464.00 to $432.00 and set a buy rating on the stock in a research report on Wednesday, July 24th.
William Blair reissued an outperform rating on shares of Medpace in a report on Wednesday, September 11th. TD Cowen lowered their target price on shares of Medpace from $452.00 to $434.
00 and set a buy rating on the stock in a report on Wednesday, July 24th. Finally, Truist Financial initiated coverage on shares of Medpace in a report on Thursday, August 1st. They set a hold rating and a $415.
00 price target for the company. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Medpace currently has a consensus rating of Moderate Buy and an average target price of $395.
00. Get Our Latest Report on Medpace Medpace Trading Up 1.6 % Medpace ( NASDAQ:MEDP – Get Free Report ) last posted its quarterly earnings data on Monday, July 22nd.
The company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.54 by $0.
21. Medpace had a return on equity of 55.14% and a net margin of 16.
74%. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.
41 million. During the same quarter in the previous year, the firm earned $1.93 EPS.
The firm’s revenue was up 14.6% compared to the same quarter last year. As a group, research analysts predict that Medpace will post 11.
66 earnings per share for the current year. Institutional Investors Weigh In On Medpace Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc.
grew its stake in shares of Medpace by 5.9% during the fourth quarter. Vanguard Group Inc.
now owns 2,556,443 shares of the company’s stock valued at $783,626,000 after purchasing an additional 142,591 shares during the last quarter. TD Asset Management Inc lifted its holdings in Medpace by 22.9% during the 1st quarter.
TD Asset Management Inc now owns 574,149 shares of the company’s stock worth $232,042,000 after buying an additional 107,108 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Medpace by 38.3% during the 2nd quarter.
Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after buying an additional 122,800 shares in the last quarter. Epoch Investment Partners Inc. boosted its position in Medpace by 15.
3% in the 1st quarter. Epoch Investment Partners Inc. now owns 406,446 shares of the company’s stock valued at $164,265,000 after buying an additional 53,983 shares during the last quarter.
Finally, Clearbridge Investments LLC raised its position in shares of Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after acquiring an additional 143,481 shares during the last quarter.
Institutional investors and hedge funds own 77.98% of the company’s stock. About Medpace ( Get Free Report ) Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. Featured Stories Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.
com's FREE daily email newsletter ..
